Table 3 Laboratory investigations, Hb and anemia at baseline and after radiotherapy for HNSCC patients with or without concomitant cetuximab
From: Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
| Â | All (n=171) | Cetuximab plus RT (n=85) | RT alone (n=86) | P value | |
|---|---|---|---|---|---|
Hb at baseline (mean (SD)) | 12.34 (2.17) | 12.20 (2.20) | 12.48 (2.14) | 0.396 | |
Hb after RT (mean (SD)) | 12.44 (2.04) | 11.98 (2.17) | 12.90 (1.80) | 0.003 | |
Anemia at baseline (n (%)) | 96 (56.1) | 48 (56.5) | 48 (55.8) | 1 | |
Anemia after RT (n (%)) | 92 (53.8) | 54 (63.5) | 38 (44.2) | 0.017 | |
Improvement of anemia or Hb levels (n (%)) | 48 (28.1) | 16 (18.8) | 32 (37.2) | 0.007 | |
CKD (n (%)) | No CKD | 155 (90.6) | 77 (90.6) | 78 (90.7) | 0.586 |
| Â | CKD 3 | 15 (8.8) | 8 (9.4) | 7 (8.1) | |
| Â | ESRD | 1 (0.6) | 0 (0.0) | 1 (1.2) | |
Vitamin B12 (n (%)) | No data | 107 (62.6) | 48 (56.5) | 59 (68.6) | Â |
| Â | Normal | 64 (37.4) | 37 (43.5) | 27 (31.4) | 1 |
Folate (n (%)) | No data | 117 (68.4) | 52 (61.2) | 65 (75.6) | Â |
| Â | Low | 2 (1.2) | 1 (1.2) | 1 (1.2) | 1 |
Iron level (n (%)) | Deficiency | 9 (5.3) | 5 (5.9) | 4 (4.7) | 0.357 |
| Â | Overload | 17 (9.9) | 9 (10.6) | 8 (9.3) | |
| Â | No data | 113 (66.1) | 51 (60.0) | 62 (72.1) | Â |